



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

27th May, 2019

Corporate Relationship Department
The BSE Ltd.
Dalal Street, Fort
Mumbai 400 001.
Scrip Code: 524816

Manager – Listing
National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051.
Scrip Code: NATCOPHARM

Dear Sir,

Sub: - Outcome of Board Meeting

We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business:

1. Audited Financial Results (Standalone and Consolidated) for the year ended 31st March, 2019 and financial results for the quarter ended 31st March, 2019 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) along with Auditor’s Report(s) of the Statutory Auditors. Please find enclosed a copy of the same for your information and a declaration as required under Listing Regulations.
2. Declaration of third (3rd) interim dividend of Rs.1.25 ps. per equity share of Rs.2/- each for the financial year 2018-19. The date for taking a record of its shareholders eligible for the purpose of payment of third (3rd) interim dividend **i.e. Record date is fixed for 07th June, 2019.** The said interim dividend will be paid on or before **14th June, 2019.**
3. Based on the recommendations of the Audit Committee, the Board of Directors recommended the appointment of M/s B S R & Associates LLP (ICAI FRN: 116231W/W-100024) as Statutory Auditors in place of retiring auditors M/s.Walker Chandiook & Co. LLP (Firm Registration No. 001076N/N500013) to hold office i.e for a period of five (5) years from the conclusion of 36th Annual General Meeting till the conclusion of the 41st Annual General Meeting of the Company (for the year 2023-2024) in compliance with mandatory rotation of auditors as per Companies Act, 2013. The details as required under Regulation 30 of SEBI (LODR) regulations, 2015 read with SEBI Circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015 are enclosed as **Annexure- I.**
4. Notice of 36th Annual General Meeting (AGM) was approved and Board had authorised Mr.V.C.Nannapaneni, Chairman and Managing Director for finalizing the date, time, venue and Book Closure dates for AGM for the financial year 2018-19.

We are also updating the financial results on the website of the Company. This is for our information and records. Please find enclosed a copy of press release for your information.

Meeting commenced at 11.00 a.m. and concluded at 4.15 p.m.

This is for our information and records.

Thanking you,
Yours faithfully,
For NATCO Pharma Limited

M. Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)

Encl: as above